FDA Expands U.S. Age Indication for EVO ICL as Long-Term Safety Data Reinforces Market Shift Away From Laser Vision Correction
STAAR Surgical Company (STAA)
Last staar surgical company earnings: 2/26 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
phx.corporate-ir.net/phoenix.zhtml?c=71327&p=irol-irhome
Company Research
Source: Business Wire
New FDA expansion of U.S. age indication extends EVO ICL use for patients 21 to 60 years old – making EVO ICL available to nearly 8 million additional refractive patientsLens-based vision correction with EVO ICL is now the leading procedure for U.S. patients with -8.0 diopters and aboveU.S. refractive market continues to shift away from laser-based refractive procedures that require corneal tissue removal LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded age indication for EVO/EVO+ Visian® Implantable Collamer Lenses, extending use to patients 21 to 60 years old. The approval came shortly after publication of three-year FDA clinical trial safety data, reinforcing the long-term safety profile of the EVO ICL.1 The EVO ICL was previously approved for U.
Show less
Read more
Impact Snapshot
Event Time:
STAA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
STAA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
STAA alerts
High impacting STAAR Surgical Company news events
Weekly update
A roundup of the hottest topics
STAA
News
- STAAR Surgical (NASDAQ:STAA) had its price target lowered by analysts at Stifel Nicolaus from $28.00 to $19.00. They now have a "hold" rating on the stock.MarketBeat
- STAAR names interim co-CEOs amid search for permanent leader [Yahoo! Finance]Yahoo! Finance
- STAAR Surgical (NASDAQ:STAA) is now covered by analysts at Wedbush. They set a "neutral" rating and a $26.00 price target on the stock.MarketBeat
- Why STAAR Surgical (STAA) Stock Is Trading Lower Today [Yahoo! Finance]Yahoo! Finance
- STAAR Surgical Appoints Warren Foust and Deborah Andrews Interim Co-CEOs [Yahoo! Finance]Yahoo! Finance
STAA
Earnings
- 11/5/25 - Beat
STAA
Sec Filings
- 2/10/26 - Form 3
- 2/5/26 - Form 8-K
- 2/4/26 - Form 4
- STAA's page on the SEC website